PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

HRA Pharma Rare Diseases funds online hub for Cushing’s Syndrome

HRA Pharma Rare Diseases, an affiliate of global consumer healthcare company HRA Pharma, has announced it is funding an online platform containing information and news on Cushing’s Syndrome.
The ‘Cushing’s Hub’, developed by Springer Healthcare Education, is set to make all information on the rare condition available in one place for medical professionals to access.
Cushing’s Syndrome affects less than one in 10,000 people in the EU, and is categorised as a rare and severe condition caused by prolonged high levels of cortisol in the blood.
The new hub is managed by an independent editorial board consisting of three international Cushing’s Syndrome experts – Professor Frédéric Castinetti from France, Dr Niki Karavitaki from the UK and Associate Professor Dr Greisa Vila from Austria.
According to HRA Pharma Rare Diseases, the ‘Cushing’s Hub’ is the first online platform dedicated to all aspects of the rare condition.
“As a company which is dedicated to improving the lives of those with rare diseases, we felt it was crucial to support the development of a platform that can help healthcare professionals in the diagnosis, management and follow up of Cushing’s Syndrome. We are confident the platform will help improve the lives of many,” said Evelina Paberž?, COO of HRA Pharma Rare Diseases.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026